In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Exact Sciences, with a price target of $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Mikson CFA has given his Buy rating due to a combination of factors, primarily driven by Exact Sciences’ strong financial performance and strategic initiatives. The company reported impressive second-quarter 2025 results, with total revenue reaching $811.1 million, marking a 16% year-over-year increase. Screening revenue, a significant contributor, grew by 18% year-over-year, showcasing robust demand for Exact’s offerings.
Additionally, Exact Sciences has secured an exclusive U.S. license for Freenome’s colorectal cancer screening test, which is expected to enhance its market position and provide long-term growth opportunities. Despite some skepticism regarding the acquisition, the deal offers strategic optionality and potential returns on investment. The company’s continued focus on developing its own CRC blood test and its commitment to joint R&D efforts further underscore its dedication to innovation and market leadership. These elements collectively justify the Buy rating, as they indicate a solid foundation for future growth and value creation.
In another report released today, Citi also maintained a Buy rating on the stock with a $65.00 price target.